Biological E.
Hyderabad, India· Est.
Indian vaccine maker Biological E leverages recombinant and conjugate platforms to supply a broad infectious‑disease portfolio across emerging markets.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Estimated funding: $150M
AI Company Overview
Indian vaccine maker Biological E leverages recombinant and conjugate platforms to supply a broad infectious‑disease portfolio across emerging markets.
VaccinesInfectious DiseaseBiologics
Technology Platform
Combines recombinant DNA expression, conjugate chemistry, and inactivated virus processes with large‑scale fermentation and aseptic fill‑finish capabilities to produce protein subunit and polysaccharide‑protein vaccines.
Opportunities
Expanding demand for affordable conjugate vaccines in emerging markets and leveraging WHO pre‑qualification to enter new geographic regions.
Risk Factors
Regulatory delays, intense price competition from larger manufacturers, and dependence on government procurement contracts.
Competitive Landscape
Competes with Serum Institute, Bharat Biotech, and global giants; differentiation lies in its conjugate vaccine expertise and rapid scale‑up capability.